Long term follow-up of the STOPAGO study

Adrien Cottu; Stéphanie Guillet; Jean-François Viallard; Etienne Riviere; Stéphane Cheze; Delphine Gobert; Antoine Neel; Julie Graveleau; Jean-Pierre Marolleau; François Lefrere; Guillaume Moulis; Jean-Christophe Lega; Aline Moignet; Ailsa Robbins; Etienne Crickx; Emmanuelle Boutin; Nicolas Noel; Marion Malphettes; Lionel Galicier; Sylvain Audia; Bernard Bonnotte; Olivier Lambotte; Olivier Fain; Mathieu Gerfaud-Valentin; Louis Terriou; Nihal Martis; Anne-Sophie Morin; Antoinette Perlat; Thomas Le Gallou; Frédérique Roy-Peaud; Matthieu Puyade; Thibault Comont; Nicolas Limal MD; Laetitia Languille; Marc Michel; Bertrand Godeau; Matthieu Mahevas

doi:10.1182/blood.2024025707

Long term follow-up of the STOPAGO study

Blood. 2024 Oct 30:blood.2024025707. doi: 10.1182/blood.2024025707. Online ahead of print.

Authors

Adrien Cottu¹, Stéphanie Guillet², Jean-François Viallard³, Etienne Riviere⁴, Stéphane Cheze⁵, Delphine Gobert⁶, Antoine Neel⁷, Julie Graveleau⁸, Jean-Pierre Marolleau⁹, François Lefrere¹⁰, Guillaume Moulis¹¹, Jean-Christophe Lega¹², Aline Moignet¹³, Ailsa Robbins¹⁴, Etienne Crickx¹⁵, Emmanuelle Boutin¹⁶, Nicolas Noel¹⁷, Marion Malphettes¹⁸, Lionel Galicier¹⁹, Sylvain Audia²⁰, Bernard Bonnotte²¹, Olivier Lambotte²¹, Olivier Fain²², Mathieu Gerfaud-Valentin²³, Louis Terriou²⁴, Nihal Martis²⁵, Anne-Sophie Morin²⁶, Antoinette Perlat²⁷, Thomas Le Gallou²⁸, Frédérique Roy-Peaud²⁹, Matthieu Puyade³⁰, Thibault Comont³¹, Nicolas Limal MD³², Laetitia Languille³³, Marc Michel³⁴, Bertrand Godeau³⁵, Matthieu Mahevas³⁶

Affiliations

¹ CHU Henri Mondor, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
² Department of Internal Medecine, Henri Mondor University Hospital, Creteil, France.
³ Haut-Leveque Hospital, Pessac, France.
⁴ Haut-Leveque Hospital, Bordeaux, France.
⁵ CHU Caen, CAEN, France.
⁶ Saint Antoine Hospital, Assistance Publique-Hôpitaux de Paris, DHU i2B, Sorbonne Université, Paris, France.
⁷ CHU de Nantes, NANTES, Alabama, France.
⁸ University Hospital of Nantes, Nantes, France.
⁹ University Hospital, Amiens, France.
¹⁰ Hôpital Necker, AP-HP, PARIS, France.
¹¹ CHU de Toulouse, Toulouse, France.
¹² Hospices Civils de Lyon, Pierre-Bénite, France.
¹³ Department of Hematology, University Hospital of Rennes, Rennes, France.
¹⁴ Robert Debré Hospital, Reims University Hospitals, Reims, France.
¹⁵ Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France.
¹⁶ Unité de Recherche Clinique (URC Mondor), Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France, Creteil, France.
¹⁷ APHP, Service de Médecine Interne, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France.
¹⁸ Hôpital Saint Louis, Paris, France.
¹⁹ Hôpital Timone, Marseille, France.
²⁰ Dijon University Hospital, DIJON, France.
²¹ Service de Medecine Interne et d'Immunologie Clinique, Centre de Reférence Constitutif des Cytopénies Auto-Immunes, Hôpital François Mitterrand, Centre Hospitalier Universitaire (CHU) Dijon-Bourgogne, France.
²² Hôpital Saint Antoine, Paris, France.
²³ Hôpital Saint Joseph Saint Luc, Lyon, France.
²⁴ hopital Cl Huriez, LILLE, France.
²⁵ Université Côte d'Azur, Nice, France.
²⁶ Centre hospitalier Robert-Ballanger, AULNAY-SOUS-BOIS, France.
²⁷ CHU Rennes, rennes, France.
²⁸ Service de Médecine Interne et Immunologie Clinique, CHU de Rennes, Rennes, France.
²⁹ CHU de Poitiers, Poitiers, France.
³⁰ CHU Poitiers, Poitiers, France.
³¹ Toulouse University Hospital, Toulouse, France.
³² Hopital Henri Mondor, APHP, Créteil, France.
³³ Assistance Publique Hôpitaux de Paris (APHP), Université Paris Est Créteil (UPEC), CRETEIL, France.
³⁴ Hôpital Henri Mondor, Créteil, France.
³⁵ APHP, UPEC, Créteil, France.
³⁶ CHU Henri Mondor, Créteil, France.

PMID: 39476101
DOI: 10.1182/blood.2024025707

Abstract

An open prospective, multicenter study enrolled 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation. NCT03119974.

Associated data

ClinicalTrials.gov/NCT03119974